2019 Volume 8 Issue 1 Pages 36-42
A medical device, “episil® Oral Liquid” (Japanese manufacturer: Solasia Pharma K. K., Tokyo, Japan), which protects the wound area of oral mucositis and relieves the pain of mucositis, was approved for inclusion in the Japanese national reimbursement pricing list in April 2018. However, the efficacy of and the feeling of use of episil® have not yet been investigated in Japan. Therefore, we conducted a case study in four patients who received hematopoietic stem cell transplantation (HSCT) at our hospital and experienced pain due to oral mucositis. At 5 minutes after an application of episil®, the oral pain scores decreased in three of the four patients, and it remained at the decreased level for 30 to 120 minutes thereafter. Two patients complained of a slight change in taste and a slight sensation of irritation, and one patient complained of a slight feeling of discomfort; however, all patients requested to continue using episil® at the completion of the pain assessment 2 hours after the application. No adverse event or adverse device deficiency was observed. These cases suggested that episil® Oral Liquid relieves the pain and discomfort of oral mucositis in patients who have received HSCT.
